Allogeneic bone marrow transplantation in mevalonic aciduria

Bénédicte Neven1, Vassili Valayannopoulos, Pierre Quartier

  • 1Unité d'Immuno-Hématologie et Rhumatologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Paris, France.

Insights

Mevalonic aciduria, a rare genetic disorder, involves recurrent fevers and inflammation. Allogeneic bone marrow transplant led to sustained remission in a young patient, offering a potential new treatment avenue.

Area of Science:

  • Biochemistry
  • Genetics
  • Immunology

Background:

  • Mevalonic aciduria is a rare autosomal recessive disorder of isoprene biosynthesis.
  • It presents with severe periodic fever, inflammation, developmental delay, ataxia, and dysmorphic features.
  • The condition results from mutations in the mevalonate kinase gene, impairing enzyme activity.

Observation:

  • A 3-year-old boy diagnosed with mevalonic aciduria showed no improvement with anti-inflammatory treatments.
  • The patient underwent an allogeneic bone marrow transplantation.
  • The donor was an HLA-identical sister who was a heterozygous carrier of the mevalonate kinase gene mutation.

Findings:

  • The bone marrow transplant resulted in sustained remission of febrile attacks and inflammation.
  • This remission was observed over a 15-month follow-up period post-transplantation.
  • The patient's condition stabilized, indicating a positive therapeutic response.

Implications:

  • Allogeneic bone marrow transplantation is a potential therapeutic strategy for severe mevalonic aciduria.
  • This approach may offer long-term disease control for patients unresponsive to conventional therapies.
  • Further research is warranted to explore the efficacy and safety of bone marrow transplantation in managing this rare genetic disorder.